Our long-term goal is to study the ubiquitin system in immune regulation. We initiated a new study of the deubiquitinating enzyme CYLD and found that deficiency of CYLD in T regulatory cells (Treg) caused chronic lung inflammation by increasing IL-4 production. These preliminary studies pointed to new mechanisms of CYLD regulation of Tregs, via modulating the cytokine production, and highlighted potential tissue-specific aspects of Treg function. Recently, we found that CYLD acts as a positive regulator in the differentiation of Treg to T follicular regulatory T cells (Tfr) in lymphoid tissues. These preliminary studies thus provide us with a solid basis for testing our central hypothesis that the ubiquitination/deubiquitination system plays a critical role in immune regulation via modulating different T cell subsets in tissue context-dependent manner. Here we plan to test this hypothesis by proposing two Specific Aims:
Aim 1, to study CYLD in Treg regulation;
and Aim 2, to study the role of CYLD in Tfr. The expected results will significantly advance our basic knowledge on the protein deubiquitination pathway in immune regulation, and will provide clues to therapeutic intervention of human diseases.

Public Health Relevance

This application will study the essential role of a protein enzyme responsible for the removal of conjugated ubiquitin from a protein substrate in immune regulation. The immune system is capable to mount robust responses against invading pathogens, but at the same time is tolerant to self-tissues or self-antigens. The mechanisms governing self-protection or immune tolerance are far from clear. The study of such mechanisms is very critical, since breakdown of immune tolerance results in disastrous consequences like the development of autoimmune diseases. This proposal will study the molecular and cellular mechanisms by which the immune responses are properly controlled by special populations of T cells. Such knowledge will eventually facilitate the design of novel therapeutic approaches for human immunological diseases.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI140130-03
Application #
9982199
Study Section
Cellular and Molecular Immunology - B Study Section (CMIB)
Program Officer
Jiang, Chao
Project Start
2018-09-19
Project End
2023-08-31
Budget Start
2020-09-01
Budget End
2021-08-31
Support Year
3
Fiscal Year
2020
Total Cost
Indirect Cost
Name
La Jolla Institute for Immunology
Department
Type
DUNS #
603880287
City
La Jolla
State
CA
Country
United States
Zip Code
92037